Omeros Corporation (OMER)

[visal]

Ditta biotecnologica con target alti
Basso flottante 32% in mano agli istituzionali
Buona cassa pochi debiti


Omeros sta sviluppando una linea profonda di prodotti candidati per il trattamento di infiammazioni, coagulopatie e disturbi del sistema nervoso centrale. Al momento sono nove programmi mirati di infiammazione , coagulopatie , più i programmi del sistema nervoso centrale e G recettori accoppiati alla proteina in fase di sviluppo, tutti i mercati di targeting di grandi dimensioni.
I nostri prodotti candidati clinicamente più avanzate in materia di infiammazione sono derivati ​​dal nostro proprietario PharmacoSurgerypiattaforma , progettato per migliorare gli esiti clinici dei pazienti sottoposti a artroscopiche , oculistiche , urologiche e altre procedure chirurgiche e mediche. In aggiunta alla nostraPharmacoSurgery

piattaforma, abbiamo un altro programma in fase di sviluppo preclinico per il trattamento di patologie infiammatorie.
Il nostro programma di sviluppo clinico per il trattamento e la prevenzione della dipendenza e dei nostri programmi preclinici di mira altri disturbi del sistema nervoso centrale e coagulopatie ampliare la nostra pipeline e contribuire a creare molteplici opportunità di successo commerciale.
Per ognuno dei nostri prodotti candidati e programmi, abbiamo mantenuto tutti i diritti di produzione, di commercializzazione e distribuzione.


Molti farmaci in cassetto due su fase tre
Io la terrei d'okkio

 

[visal]

Graficamente non messa male
Che ne pensate??

 

[visal]

+4.44%

 

[legolego]

Occhissimo ...
nel 1° del 2013 dovrebbero annunciare inizio di altre fase 3 (per non ricordo quale composto).

Cerco la notizia ...

 

[legolego]

Inoltre:

Omeros' objective is to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration in the first quarter of 2013 and a Marketing Authorization Application (MAA) with the European Medicines Agency in mid-2013

Omeros to present results from first pivotal Phase 3 trial of OMS302 at AAO annual meeting

 

[legolego]

Shares of Omeros (OMER) were falling more than 11% in recent trading, following news late Thursday that the drug maker’s OMS103HP treatment missed some trial targets.

Omeros said that patients undergoing arthroscopic knee surgery did demonstrate some positive results in its Phase 3 clinical trial, noting that its plans for future study in the first half of 2013 are on track.

Nonetheless, it noted that some significant recovery benefits seen in a Phase 2 trial did not occur, even as it did show “statistically significant reduction of postoperative pain.”

OMS103HP is being closely watched as it is one of the company’s two most promising potential products.

Needham analyst Adam Carr expects that Omeros may need to do two more trials, focusing on pain as “the primary endpoint” to gain approval from the Food and Drug Administration.

In a note out today, he writes “We believe OMS103HP has utility in knee surgery, given the known anti-inflammatory activity of its three components. The absence of a consistent, comprehensive positive signal from the Phase 2 and 3 trials, however, suggests that the overall impact may be modest. We nevertheless reiterate our Buy rating based primarily on success of the OMS302 ophthalmology program, which may reach the market in early 2014.”

Mixed Phase 3 Trials For Omeros Treatment Sinks Stock | Global Regulatory Science

 

[tiopentone]

Merita l'ingresso in "wacht list"....

 

[Dave79]

Omeros Corporation : Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial | 4-Traders

 

[tiopentone]

Omeros Corporation : Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial | 4-Traders

Non mi sembra male, anzi...e allora?

 

[massimomassimo]

Massacrata dall'emissione atm.adesso dovrebbero averla chiusa.si attendono news importanti entro giungno/luglio.base di accumulo

 

[massimomassimo]

anche qua stanno costruendo la base))dovremmo essere quasi pronti))

 

[ettore7001]

più che una base hanno fatto un recintoha fatto un buon movimento di un dollaro,adesso sta cercando di saltare la media
sopra 5,25 entro

 

[mignolomi]

nei forum Usa parlano di un target di 12 $ giù domani...

 

[mignolomi]

 

[ilpensionato]

ho guardato meglio e graficamente lo puo fare, non è messa male..........pero il rischio esiste eccome

 

[LOROCIU65]

Omeros Reports Additional Positive Results from OMS824 Program

ma e' fase 1-- poi flottanteb basso fanno come gli Pare

 

[federico il duca]

rifatto i massimi spacca

 

[mignolomi]

confermo 12 dollari domani ( fonte forum Usa )

 

[marxlago]

Omeros Reports Additional Positive Results from OMS824 Program

ma e' fase 1-- poi flottanteb basso fanno come gli Pare

Cash?
Ca

 

[mignolomi]

Omeros rises as analyst lifts price target
Omeros jumps after analyst upbeat on sales potential for ophthalmology drug OMS302

NEW YORK (AP) -- Shares of drug developer Omeros surged Monday after an analyst took a more positive view of the company's experimental ophthalmology drug OMS302.
THE SPARK: Wedbush analyst Liana Moussatos noted that eye care specialists believe the Food and Drug Administration is becoming stricter about the sterilization of drugs used in lens replacement surgeries. She said cataract surgeons report that the agency is requiring them to use separate bottles of different medications and barring them from mixing medications themselves. The changes effectively make current medications more costly and would make OMS302 seem less expensive, she said.
Moussatos rates Omeros shares "Outperform" and she raised her price target to $28 per share from $18.
THE BIG PICTURE: Omeros Corp. does not have any approved drugs. The Seattle company asked the FDA to approve OMS302 in August, and it filed for European Union marketing approval in September.
OMS302 is a combination of two topical drugs that are used in lens replacement surgeries for cataracts and other conditions. One component causes pupil dilation and the other is an anti-inflammatory drug intended to reduce pain and irritation after surgery. Moussatos says she thinks annual sales of OMS302 could reach $479 million a year at their peak.
The company's other experimental drugs include OMS103HP, which is intended to reduce early pain after arthroscopic surgery, and OMS201, an anti-inflammatory drug and muscle relaxant intended for use during urology procedures.
SHARE ACTION: Shares of Omeros climbed $3.47, or 68 percent, to close at $8.56. The shares peaked earlier at $8.64, their highest price in 2013. In April the shares traded as low as $3.65.


in pratica il titolo Omer arriverà a 28$ ????